Cipla Limited
https://www.cipla.com/home
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cipla Limited
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
Spluttering US Generics Landscape Shows Signs Of Promise In Q2
High-value launches and an improving broader landscape for generic pricing provided a fillip for some US generics manufacturers in the second quarter, although others disclosed that they were still weathering the storm as the end of the year approaches.
Spluttering US Generics Landscape Shows Signs Of Promise In Q2
High-value launches and an improving broader landscape for generic pricing provided a fillip for some US generics manufacturers in the second quarter, although others disclosed that they were still weathering the storm as the end of the year approaches.
Company Information
- Industry
- Contract Research Organization-CRO
- Medical Devices
- Pharmaceuticals
-
Services
- Consulting Services
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Nutraceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Cipla Gulf FZ LLC
- Cipla Technologies LLC
- InvaGen Pharmaceuticals Inc.
- Mirren Pty, Ltd.